Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cyberonics' delight at US move on VNS therapy for depression

This article was originally published in Clinica

Executive Summary

A pacemaker-like device that fires mild electrical impulses into the vagus nerve should be allowed onto the US market to treat chronic depression, an FDA advisory panel decided on June 15. The neurological devices panel voted 5-2 to recommend that the VNS Therapy System, manufactured by Houston, Texas-based Cyberonics, be approved subject to certain conditions, despite their concerns about the clinical data and the possibility that the results were merely a placebo effect.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058763

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel